Krystal Biotech, Inc. KRYS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $116.36M+31.9% | $107.11M+17.5% | $97.8M+16.6% | $96.04M+36.6% | $88.18M+94.9% | ||
| $15.33M+7.5% | $14.79M+9.4% | $14.59M+7.9% | $14.41M-7.5% | $14.26M+30.1% | ||
| $41.01M+25.6% | $41.45M+32.5% | $37.58M+31.1% | $35.16M+27.3% | $32.65M+25.3% | ||
| $62.67M+20.7% | $62.84M+26.3% | $56.43M-8.1% | $56.74M-8.1% | $51.93M0.0% | ||
| $62.67M+20.7% | $62.84M+26.3% | $56.43M-8.1% | $56.74M-8.1% | $51.93M0.0% | ||
| $53.69M+48.1% | $44.27M+7.0% | $41.37M+84.1% | $39.31M+359% | $36.25M+642% | ||
| 46.1%+5.0pp | 41.3%-4.1pp | 42.3%+15.5pp | 40.9%+28.7pp | 41.1%+55.9pp | ||
| $7.75M+5.6% | $6.86M-5.2% | $6.59M-9.6% | $7.47M-0.1% | $7.35M-3.6% | ||
| $61.44M+40.9% | $51.13M+5.2% | $47.97M+61.1% | $46.78M+192% | $43.6M+4,578% | ||
| $5.51M-29.9% | -$269K-109% | -$31.4M-1,313% | $8.44M+1,670% | $7.86M— | ||
| $55.93M+56.5% | $51.4M+13.0% | $79.37M+192% | $38.33M+146% | $35.73M+3,734% | ||
| 48.1%+7.5pp | 48%-1.9pp | 81.2%+48.7pp | 39.9%+17.8pp | 40.5%+38.5pp | ||
| $1.83+52.5% | $1.70+11.1% | $2.66+192% | $1.29+143% | $1.20+3,900% | ||
| $1.91+54.0% | $1.77+11.3% | $2.74+188% | $1.33+146% | $1.24+4,033% | ||
| 30.5M+2.1% | 30M+0.7% | 29.8M-0.2% | 29.7M+0.4% | 29.9M+2.0% | ||
| 29.3M+1.6% | 28.9M+1.2% | 29M+0.8% | 28.9M+1.1% | 28.8M+1.8% | ||
| $6.32M+25.8% | $6.59M+33.2% | $4.26M-36.2% | $7.17M+19.2% | $5.03M+108% | ||
| —— | $0+100% | $0+100% | $0+100% | $0+100% | ||
| $7.75M+5.6% | $6.86M-5.2% | $6.59M-9.6% | $7.47M-0.1% | $7.35M-3.6% | ||
| $53.17M+46.4% | $51.44M+17.5% | $79.31M+170% | $39.1M+157% | $36.31M+726,360% | ||
| $1.52M+7.9% | $1.56M+14.5% | $1.4M+7.7% | $1.3M-27.8% | $1.41M-1.2% | ||
| -$1.58M-558% | —— | $657K-64.3% | -$158K+37.3% | $344K+139% | ||
| $116.36M+31.9% | $107.11M+17.5% | $97.8M+16.6% | $96.04M+36.6% | $88.18M+94.9% | ||
| $53.69M+48.1% | $44.27M+7.0% | $41.37M+84.1% | $39.31M+359% | $36.25M+642% | ||
| $55.21M+46.6% | $45.83M+7.2% | $42.77M+79.9% | $40.61M+292% | $37.66M+816% | ||
| $55.21M+46.6% | $45.83M+7.2% | $42.77M+79.9% | $40.61M+292% | $37.66M+816% | ||
| 47.4%+4.7pp | 42.8%-4.1pp | 43.7%+15.4pp | 42.3%+27.5pp | 42.7%+54.3pp | ||
| $53.69M+48.1% | $44.27M+7.0% | $41.37M+84.1% | $39.31M+359% | $36.25M+642% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Krystal Biotech, Inc.'s revenue?
- Krystal Biotech, Inc. (KRYS) generated $417.3M in revenue over the trailing twelve months, up 25.1% year over year.
- Is Krystal Biotech, Inc. profitable?
- Krystal Biotech, Inc. reported $225.0M in net income over the trailing twelve months, a 53.9% net margin.
- What is Krystal Biotech, Inc.'s earnings per share?
- Krystal Biotech, Inc.'s diluted EPS over the trailing twelve months is $7.48.
- Where does Krystal Biotech, Inc.'s income statement data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
